{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T12:10:26Z","timestamp":1785327026324,"version":"3.55.0"},"reference-count":24,"publisher":"MDPI AG","issue":"8","license":[{"start":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T00:00:00Z","timestamp":1785283200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Life"],"abstract":"<jats:p>Cutaneous graft-versus-host disease (GVHD) is a common complication of allogeneic haematopoietic stem cell transplantation (allo-HSCT). Despite established guidelines, discrepancies persist between clinical trial evidence and real-world practice, particularly for newer agents such as ruxolitinib. To characterize the phenotypic spectrum of cutaneous GVHD, evaluate real-world treatment strategies\u2014with a specific focus on systemic and topical ruxolitinib\u2014and assess adherence to national and international guidelines, we conducted a retrospective observational study of patients undergoing allo-HSCT between 2015 and 2025 who were referred to a dedicated dermato-haematology clinic. Clinical, histological, and therapeutic data were collected. Cutaneous manifestations were classified according to National Institutes of Health (NIH) and Italian Group for Blood and Marrow Transplantation (GITMO) criteria. Of 62 transplanted patients, 44 (71%) developed GVHD, with the skin as the most frequently involved organ. Acute GVHD predominantly presented with maculopapular eruptions, whereas chronic GVHD showed heterogeneous phenotypes, including sclerotic variants. First-line management was largely guideline-concordant. Systemic ruxolitinib was administered to 3% of patients in the aGVHD group and 3% in the cGVHD group. Steroid-refractory and steroid-dependent status was not systematically recorded; therefore, treatment eligibility could not be reliably determined, and the observed frequencies should not be interpreted as evidence of underuse. Topical ruxolitinib was not used and remains investigational for cutaneous GVHD. Interpretation should also consider that the study period encompassed changes in regulatory approval, reimbursement, and access to targeted therapies. Structured multidisciplinary assessment may support the management of complex cutaneous GVHD, although its effects on treatment decisions and patient outcomes require prospective evaluation.<\/jats:p>","DOI":"10.3390\/life16081255","type":"journal-article","created":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T11:45:14Z","timestamp":1785325514000},"page":"1255","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Cutaneous Graft-Versus-Host Disease After Allogeneic Hematopoietic Stem Cell Transplantation: A Single-Center Retrospective Cohort Study of Clinical Spectrum and Treatment Patterns"],"prefix":"10.3390","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0849-715X","authenticated-orcid":false,"given":"Annunziata","family":"Raimondo","sequence":"first","affiliation":[{"name":"Department of Medicine Surgery and Dentistry, \u201cScuola Medica Salernitana\u201d, University of Salerno, 84084 Salerno, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1838-1484","authenticated-orcid":false,"given":"Annunziata","family":"Nigro","sequence":"additional","affiliation":[{"name":"Department of Medicine Surgery and Dentistry, \u201cScuola Medica Salernitana\u201d, University of Salerno, 84084 Salerno, Italy"},{"name":"Graduate School in Clinical Pathology and Clinical Biochemistry, University of Salerno, Baronissi, 84081 Salerno, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mara","family":"Corbisieri","sequence":"additional","affiliation":[{"name":"Department of Medicine Surgery and Dentistry, \u201cScuola Medica Salernitana\u201d, University of Salerno, 84084 Salerno, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7492-6848","authenticated-orcid":false,"given":"Valentina","family":"Giudice","sequence":"additional","affiliation":[{"name":"Department of Medicine Surgery and Dentistry, \u201cScuola Medica Salernitana\u201d, University of Salerno, 84084 Salerno, Italy"},{"name":"Hematology and Transplant Center, University Hospital \u201cSan Giovanni Di Dio E Ruggi d\u2019Aragona\u201d, 84131 Salerno, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bianca","family":"Serio","sequence":"additional","affiliation":[{"name":"Hematology and Transplant Center, University Hospital \u201cSan Giovanni Di Dio E Ruggi d\u2019Aragona\u201d, 84131 Salerno, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Serena","family":"Lembo","sequence":"additional","affiliation":[{"name":"Department of Medicine Surgery and Dentistry, \u201cScuola Medica Salernitana\u201d, University of Salerno, 84084 Salerno, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5861-8984","authenticated-orcid":false,"given":"Carmine","family":"Selleri","sequence":"additional","affiliation":[{"name":"Department of Medicine Surgery and Dentistry, \u201cScuola Medica Salernitana\u201d, University of Salerno, 84084 Salerno, Italy"},{"name":"Hematology and Transplant Center, University Hospital \u201cSan Giovanni Di Dio E Ruggi d\u2019Aragona\u201d, 84131 Salerno, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,7,29]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"2550","DOI":"10.3324\/haematol.2019.240309","article-title":"Translational and clinical advances in acute graft-versus-host disease","volume":"105","author":"Gooptu","year":"2020","journal-title":"Haematologica"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"5","DOI":"10.2991\/chi.d.200115.001","article-title":"Current Status and Future Directions in Graft-Versus-Host Disease Prevention Following Allogeneic Blood and Marrow Transplantation in Adults","volume":"2","author":"Tegla","year":"2020","journal-title":"Clin. Hematol. Int."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"515.e1","DOI":"10.1016\/j.jaad.2011.11.960","article-title":"Graft-versus-host disease: Part I. Pathogenesis and clinical manifestations of graft-versus-host disease","volume":"66","author":"Hymes","year":"2012","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Zeiser, R., Ringden, O., Sadeghi, B., Gonen-Yaacovi, G., and Segurado, O.G. (2023). Novel therapies for graft versus host disease with a focus on cell therapies. Front. Immunol., 14.","DOI":"10.3389\/fimmu.2023.1241068"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"S46","DOI":"10.1016\/j.bbmt.2011.10.021","article-title":"Fibrotic and sclerotic manifestations of chronic graft-versus-host disease","volume":"18","author":"Kitko","year":"2012","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.bbmt.2014.12.001","article-title":"National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group report","volume":"21","author":"Jagasia","year":"2015","journal-title":"Biol. Blood Marrow Transpl."},{"key":"ref_7","unstructured":"Justiz Vaillant, A.A., Modi, P., and Mohammadi, O. (2025). Graft-Versus-Host Disease. StatPearls, StatPearls Publishing LLC."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/j.jtct.2021.03.033","article-title":"National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: IIa. The 2020 Clinical Implementation and Early Diagnosis Working Group Report","volume":"27","author":"Kitko","year":"2021","journal-title":"Transplant. Cell Ther."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"S513","DOI":"10.1016\/j.jtct.2024.05.020","article-title":"Cutaneous Chronic Graft-Versus-Host Disease: Clinical Manifestations, Diagnosis, Management, and Supportive Care","volume":"30","author":"Shi","year":"2024","journal-title":"Transplant. Cell Ther."},{"key":"ref_10","unstructured":"Italian Group for Blood and Marrow Transplantation (GITMO) (2024). Guidelines for the Prophylaxis and Treatment of Acute and Chronic Graft-Versus-Host Disease, Italian Group for Blood and Marrow Transplantation (GITMO)."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1056\/NEJMoa2033122","article-title":"Ruxolitinib for Glucocorticoid-Refractory Chronic Graft-versus-Host Disease","volume":"385","author":"Zeiser","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1016\/j.bbmt.2010.06.015","article-title":"Consensus conference on clinical practice in chronic graft-versus-host disease (GVHD): First-line and topical treatment of chronic GVHD","volume":"16","author":"Wolff","year":"2010","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1182\/hematology.2021000301","article-title":"Updates in chronic graft-versus-host disease","volume":"2021","author":"Hamilton","year":"2021","journal-title":"Hematol. Am. Soc. Hematol. Educ. Program."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1182\/blood-2006-01-0233","article-title":"Rituximab for steroid-refractory chronic graft-versus-host disease","volume":"108","author":"Cutler","year":"2006","journal-title":"Blood"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1056\/NEJMoa1917635","article-title":"Ruxolitinib for Glucocorticoid-Refractory Acute Graft-versus-Host Disease","volume":"382","author":"Zeiser","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"977","DOI":"10.2217\/imt-2021-0013","article-title":"Ruxolitinib, a JAK1\/JAK2 selective inhibitor, ameliorates acute and chronic steroid-refractory GvHD mouse models","volume":"13","author":"Huarte","year":"2021","journal-title":"Immunotherapy"},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Zhang, M.Y., Zhao, P., Zhang, Y., and Wang, J.S. (2022). Efficacy and safety of ruxolitinib for steroid-refractory graft-versus-host disease: Systematic review and meta-analysis of randomised and non-randomised studies. PLoS ONE, 17.","DOI":"10.1371\/journal.pone.0271979"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1182\/blood.2020004823","article-title":"Ruxolitinib for the treatment of steroid-refractory acute GVHD (REACH1): A multicenter, open-label phase 2 trial","volume":"135","author":"Jagasia","year":"2020","journal-title":"Blood"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"43.e1","DOI":"10.1016\/j.jtct.2021.10.015","article-title":"Efficacy and Safety of Ruxolitinib in Steroid-Refractory\/Dependent Chronic Graft-versus-Host Disease: Real-World Data and Challenges","volume":"28","author":"Redondo","year":"2022","journal-title":"Transplant. Cell Ther."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1016\/j.bbmt.2019.04.003","article-title":"Efficacy, Toxicity, and Infectious Complications in Ruxolitinib-Treated Patients with Corticosteroid-Refractory Graft-versus-Host Disease after Hematopoietic Cell Transplantation","volume":"25","author":"Abedin","year":"2019","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"2222","DOI":"10.1111\/jdv.19162","article-title":"Topical ruxolitinib: A new treatment for vitiligo","volume":"37","author":"Tavoletti","year":"2023","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1080\/1744666X.2024.2435657","article-title":"An evaluation of the recently approved drugs for treating atopic dermatitis in the context of their safety and efficacy: A systematic review and meta-analysis","volume":"21","author":"Alkattan","year":"2025","journal-title":"Expert Rev. Clin. Immunol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1038\/s41409-023-02181-3","article-title":"Topical ruxolitinib is promising as sole or adjunctive therapy in treating maculopapular rash of acute and chronic skin GVHD","volume":"59","author":"Hudda","year":"2024","journal-title":"Bone Marrow Transpl."},{"key":"ref_24","first-page":"S1","article-title":"Phase 2 Trial of Ruxolitinib Cream for Chronic Cutaneous GvHD","volume":"30","author":"Markova","year":"2024","journal-title":"Transplant. Cell. Ther. Off. Publ. Am. Soc. Transplant. Cell. Ther."}],"container-title":["Life"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2075-1729\/16\/8\/1255\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T11:56:39Z","timestamp":1785326199000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2075-1729\/16\/8\/1255"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,29]]},"references-count":24,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2026,8]]}},"alternative-id":["life16081255"],"URL":"https:\/\/doi.org\/10.3390\/life16081255","relation":{},"ISSN":["2075-1729"],"issn-type":[{"value":"2075-1729","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,29]]}}}